European journal of radiology · 2026
Contrast enhanced ultrasound at first month: A feasible predictor for retreatment after benign thyroid nodule thermal ablation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yin Tinghui, Leng Yifei, Zheng Bowen, Wang Jinfen, Tan Lei, He Yuting, Lian Yufan, Ma Yanping, Tong Ge, Chen Xiuling, Wu Tao, Ren Jie
Аннотация
OBJECTIVES: To determine the clinical values of contrast enhanced ultrasound (CEUS) at the first follow-up for predicting retreatment in benign thyroid nodules (BTNs) after thermal ablation (TA).
MATERIALS AND METHODS: A total of 176 BTNs from 155 patients who underwent TA with a median follow-up period of 32.5 months (range 7 to 83 months) were enrolled in this study. Initial ablation ratio (IAR) and CEUS base IAR (CIAR) was calculated by conventional US and CEUS at 1-month after TA. The predicting performances for retreatment of quantitative and qualitative CEUS at 1-month after TA were analyzed by receiver operating characteristic (ROC) curves and Kaplan-Meier survival analysis.
RESULTS: The median final volume reduction rate (VRR) of all nodules was 96.9% (range 31.4% to 100%). The areas under curves (AUCs) of quantitative and qualitative CEUS at 1-month for nodular retreatment were 0.986 and 0.981. Correspondingly, the sensitivity, negative predictive value (NPV) and negative likelihood ratio (LR) were 100%, 100% and 0 for both quantitative and qualitative CEUS.
CONCLUSION: CEUS at 1-month is a feasible predictor for nodular retreatment after BTNs TA. According to our results, CEUS is recommended as routine at the first follow-up for BTNs underwent TA.
MATERIALS AND METHODS: A total of 176 BTNs from 155 patients who underwent TA with a median follow-up period of 32.5 months (range 7 to 83 months) were enrolled in this study. Initial ablation ratio (IAR) and CEUS base IAR (CIAR) was calculated by conventional US and CEUS at 1-month after TA. The predicting performances for retreatment of quantitative and qualitative CEUS at 1-month after TA were analyzed by receiver operating characteristic (ROC) curves and Kaplan-Meier survival analysis.
RESULTS: The median final volume reduction rate (VRR) of all nodules was 96.9% (range 31.4% to 100%). The areas under curves (AUCs) of quantitative and qualitative CEUS at 1-month for nodular retreatment were 0.986 and 0.981. Correspondingly, the sensitivity, negative predictive value (NPV) and negative likelihood ratio (LR) were 100%, 100% and 0 for both quantitative and qualitative CEUS.
CONCLUSION: CEUS at 1-month is a feasible predictor for nodular retreatment after BTNs TA. According to our results, CEUS is recommended as routine at the first follow-up for BTNs underwent TA.